Market access webinar

Navigating the cell and gene therapy market access landscape

Fill in your details to watch this webinar

We respect your privacy. Cookie policy.

December 7 2022, 7am PST, 10am EST, 3pm GMT, 11pm SGT

This webinar explores the cell and gene therapy (CGT) landscape, highlighting key market access challenges, and concludes with considerations for optimizing patient access.

This webinar will provide: 

a summary of the evolving treatment landscape in cell and gene therapies

an overview of the key challenges to overcome for achieving optimal access, including:

– demonstrating long-term benefit and managing data collection uncertainties

– affordability of ‘”one-off’” high-cost treatments paid over a short duration

– optimizing product positioning and demonstrating value versus competitors

– managing complexities around small patient pools

practical considerations on overcoming market access challenges and key barriers for cell and gene therapies

Presenters:

    

Sanjeev has a number of years of market access experience. He has held senior leadership roles within the pharmaceutical industry and recently led launch excellence activities in cellular therapy covering all aspects from access to operational implementation.

His experience spans translational medicine, health systems, and commercialization in drug development and diagnostics. Sanjeev has a deep interest in cell and gene therapy, companion diagnostics, clinical pathways, real-world data, and cancer systems.

He has expertise across a number of disease areas with a specialism in oncology/hematology.

 

  

As the leader of the Market Access Practice at Avalere, Lance Grady devises commercialization strategies focused on value, access, and reimbursement.

With a focus in oncology and autoimmune disease, and over 20 years of experience in policy, access, and reimbursement strategy, he provides practical and meaningful advisory services to healthcare stakeholders.

Lance delivers proven, measurable outcomes by creating integrative and sustainable solutions in functional areas pertaining to drug value and pricing; health plan and payer engagement strategy; benefit design, patient affordability, and access strategy and services; drug-dollar-data flow for medical and pharmacy benefit; oncology pathways; specialty channel strategies; and CMS policy strategy with a focus on coverage, reimbursement, and alternative payment models.

 

Sudha has 7 years’ experience working across market access consulting, life sciences academic research, and business development, partnering with pharmaceutical and medical device companies in the APAC region.

She has led and contributed to multiple market access projects involving market opportunity assessment, pricing and reimbursement potential evaluation, real-world evidence capabilities mapping, as well as new technology scoping projects.

Her work has spanned multiple therapeutic areas including rare diseases, oncology (with a focus on innovative therapies such as CAR-Ts), vascular disorders, mental health, cardiometabolic as well as infectious diseases in APAC countries.

 

Ye has several years’ consultancy experience in health technology assessment and market access across Europe, Asia, the Middle East, and Latin America.

At PRMA Consulting she has worked on multiple projects on market access, pricing and reimbursement strategy, market risks and opportunity assessments, evidence generation planning, and cost-effectiveness and budget impact modeling. Her experience spans a range of therapeutic areas, particularly mood disorders, autoimmunology, rare diseases, oncology, and ophthalmology, with an interest focusing on gene therapies.

Duration: 20 minutes.

Broadcast: 2022 

Previous webinars

Understanding the concept of early scientific advice and its purpose across HTA markets

Read more >

Increase your influence in early pipeline planning: why earlier value assessment of your assets through a payer lens makes a difference.

Read more >

How to demonstrate the value of vaccines in line with global NITAG and HTA requirements

Read more >

Market access for biotechnology

Read more >

How to build an optimized GVD to populate local HTA/payer templates

Read more >

Recommendations for driving your journey to digital excellence

Read more >

The PRMA Healthcheck®: the future of market access in Asia-Pacific

Read more >

PRMA Healthcheck® for assets in early stages of clinical development

Read more >

The evolution of the PRMA Healthcheck® for US payer archetypes

Read more >

Navigating the updated 2020 ICER value assessment framework

Read more >

Accelerate the time to patient access with the PRMA Navigator®

Read more >

EUnetHTA joint clinical assessments: where have we come from and where are we going?

Read more >

Future proofing for the 2020s market access trends

Read more >

Managed entry agreements: lessons from EU5

Read more >

CAR-T therapy: the future begins to take shape

Read more >

Indication-specific pricing: the obvious solution

Read more >

Payer perspectives on cell and gene therapies: opportunities and challenges

Read more >

Market access considerations for CAR-Ts: insights from ASH

Read more >

Patient-centricity: shaping value generation for HTA and market access

Read more >

Market access for PD-1 inhibitors: where are we now?

Read more >

Does 1+1 always equal 2? Valuing combinations

Read more >

Clarity or confusion: the role of value frameworks in oncology

Read more >